Clinical trials present a new approach using immunotherapy

After 40 years of treating metastatic bladder cancer with chemotherapy as a primary treatment, scientists now present a new approach using immunotherapy combinations. The results of two studies have been presented at the European Society for Medical Oncology (ESMO) conference in Madrid. The outcomes of these studies could revolutionize the landscape of bladder cancer treatment.

Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer

Cancers, Free Full-Text

IMMUNOTHERAPY ASSAYS, Top CRO for Bioanalysis - Marin Biologic Laboratories

cellular and molecular pharmacology - presentation

Immunotherapy approaches for hematological cancers - ScienceDirect

JCI - Progress on new vaccine strategies for the immunotherapy and prevention of cancer

Frontiers Next Generation CD40 Agonistic Antibodies for Cancer Immunotherapy

Tumor Microenvironment Program - USC Norris Comprehensive Cancer Center

Review paper compares two leading pancreatic cancer drugs

A New Biomarker for Response to Checkpoint Inhibitors - NCI

Immunotherapy combination approaches: mechanisms, biomarkers and clinical observations

Delivery strategies of cancer immunotherapy: recent advances and future perspectives, Journal of Hematology & Oncology

Clinical Trials Roswell Park Comprehensive Cancer Center - Buffalo, NY

Use of Predictive Biomarkers, Incorporating Chemotherapy—What Is Best When Using Immunotherapy in Advanced NSCLC? - (ILCN/WCLC)